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Abstract
The management of patients with both types of infl ammatory bowel disease (IBD), Ulcerative Colitis and 
Crohn’s Disease, varies in medical centers around the world. Recognition of this variability in patient manage-
ment is the initial step in improving the quality of care of IBD patients. The need for improvement is refl ected in 
the overuse, underuse or misuse of medical services currently available. Having the appropriate knowledge, 
well adjusted to medical recommendations based on clinical evidence is important if we are to give our pa-
tients the best care. This review will provide recommendations regarding IBD patient treatment quality, as well 
as for prevention of complications associated with the disease and established medical treatment.
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INTRODUCTION
Basing patient care quality on accepted international stan-
dards is the main mechanism by which we can provide a 
level of adequate health care to the population. In 1990 the 
Institute of Medicine in the USA defi ned quality health as, 
“Th e quality of care in which health services increase the 
possibility of desired outcomes in patients, which are con-
sistent with current medical knowledge.” 
A random population study of 12 U.S. cities which sur-
veyed 6,712 adults asked about quality management and 
found that only 54.9% of individuals receive recommended 
care. Th e proportion of acute care was 53.5%, 56.1% for 
chronic conditions and 52.2% for preventive care (1). A 
similar study of the same group which surveyed 1,536 chil-
dren in the same cities found that 46.5% of them receive 
the recommended care. Th e proportion of acute care was 
67.6%, 53.4% for chronic conditions and 40.7% for preven-
tive actions (2). 
It is therefore important to have the appropriate 
knowledge adjusted to established medical recommen-
dations to give our patients the best care. We see this in 
our daily practice where overuse, underuse or wrong use 
of the medical resources we have at our disposal is seen. 
Recognition of the variability of patient management is the 
initial step for improving quality of care. 
Th ere is great variability in the management of patients 
with infl ammatory bowel disease (IBD) around the world. 
A study of 64 patients att ending consultation for a second 
opinion at the Women’s Hospital in Boston assessed adhe-
rence to established guidelines. It found that 64% were 
receiving suboptimal doses of aminosalicylates (5-ASA). 
75% with ulcerative distal colitis did not receive topi-
cal 5-ASA and 77% of patients had received steroids for 
more than 3 months. No att empt had been made to treat 
59% of patients with alternatives to steroids such as other 
immunosuppresors or biological therapy with antibodies 
against tumor necrosis factor (anti-TNF). 82% of patients 
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using azathioprine had sub-therapeutic doses while 78% of 
patients received steroid treatment inadequate for preven-
tion of metabolic bone disease. 33% of patients with indi-
cations for monitoring colorectal cancer or dysplasia did 
not undergo colonoscopies (3). Another study in China 
found that only 54.4% of patients with distal colitis recei-
ved topical 5-ASA, 27.8% of patients with severe IBD were 
not treated with steroids and only 19.6% of patients with 
indications for thiopurines received them. 57% of them 
were given suboptimal doses (48). 
A survey of 186 members of the American 
Gastroenterological Association about management of 
Crohn’s disease found a high rate of prescription of 5-ASA 
although litt le evidence exists for its clinical use. It was 
especially prescribed by physicians who were not experts 
in the management of IBD (49).
Vaccinations against preventable disease are important, 
especially for immunosuppressed patients with IBD. A 
recent study found that only 45% of these patients recei-
ved tetanus vaccinations in the previous 10 years, only 28% 
had annual infl uenza vaccinations, only 9% were vaccina-
ted against pneumonia, and only 33% of at risk patients had 
hepatitis B immunization (4). 
QUALITY IN TREATMENT OF IBD 
Initial treatment of patients with mild to moderate ulce-
rative colitis is based on 5-ASA derivatives. Th e presenta-
tion to be used depends on the extent of the disease. For 
patients with ulcerative proctitis, the recommendation is to 
use 1g/day treatment with 5-ASA suppositories. Liquid or 
foam enemas are preferable because they are more eff ective 
than oral 5-ASA derivatives and topical steroids (5,6). A 
metaanalysis of patients with active proctitis showed that 
the average remission rate for treatment with topical 5-ASA 
derivatives was 67% while the placebo response was 11% 
(7). For patients with the last 50 cm of the colon compro-
mised by colitis, a combination of topical 5-ASA derivatives 
with oral 5-ASA is bett er than administering either sepa-
rately (8) as patients with extensive colitis do not initially 
respond to oral 5 -ASA, but do benefi t from the addition of 
topical 5-ASA (9). 
Patients with mild to moderate ulcerative colitis that does 
not respond to treatment with 5-ASA derivatives within 2 
weeks should receive oral steroids. Th e recommended daily 
dose is 40 mg of oral prednisone. Th is should be gradually 
decreased by 5 to10 mg every week aft er clinical remission 
has been achieved until the dosage reaches 20 mg/day. 
At that point daily dosage is should be reduced by 2.5 mg 
every week until treatment is suspended (10). Similarly, 
maximum recommended duration of steroid treatment is 
12 to 16 weeks. Patients who require more than 1 or 2 cour-
ses of steroid treatment a year or who are steroid dependent 
(those unable to reduce doses of prednisone below 10 mg/
day or reduce budesonide doses below 3 mg/day in 3 mon-
ths who or relapse within 3 months aft er discontinuation) 
require steroid sparing strategies such as the use of other 
immunosuppressants or biological therapy (11). 
It is well established that the best way to maintain clinical 
remission of Crohn’s disease is to administer 2.5 mg/kg/
day doses of azathioprine. A recent Cochrane review found 
that the OR of eff ectiveness with this dosage is 4.1, while 
for doses of 2.0 mg/kg/day it is 3.0 and for 1.0 mg/kg/day 
it is 1.2 (12). 
Safety of the use of certain medications prior to surgery 
for patients with Crohn’s disease and ulcerative colitis 
is quite controversial. Th ere is a consensus that predni-
sone dosage of over 20 mg/day for more than 6 weeks is 
a risk factor for surgical complications. Th is drug should 
be discontinued if possible prior to surgery. If the patient 
has received steroids for 1 to 3 months, the rate of dosage 
decrease should be 5 mg per week, but if the treatment had 
been for 3 to 6 months, the reduction should be 2.5 mg per 
week. In contrast, thiopurines such as azathioprine appear 
to be safe in this context (17, 18). 
Th e relation between peri-operative use of anti-TNF the-
rapy and the risk of postoperative complications remains 
controversial. A recent metaanalysis of 5 studies and 706 
patients has shown a higher than normal rate of postope-
rative complications among patients with who received 
anti-TNF therapy (OR 1.8). Th is was especially pronoun-
ced for patients with infectious ulcerative colitis (OR 2.24) 
(19). Th is has not been demonstrated in patients with 
Crohn’s disease. Furthermore, there is no consensus on the 
minimum time required between suspension of anti-TNF 
therapy and surgery. Some say that the time should be a 
month, but therapeutic concentrations of infl iximab have 
been were detected for up to 8 weeks aft er infusion (6,20). 
Frequently, diagnosis of Crohn’s disease in Colombia 
occurs aft er an urgent surgical procedure. We know that 
60% to 75% of patients with Crohn’s disease require sur-
gical treatments at diff erent points of their lives because of 
complications associated with stricturing or penetrating. 
It has been estimated that 70% of patients require further 
surgery aft er 20 years of follow-up. Surgery is not curative, 
and symptoms recur in 30% of patients aft er 3 years, and in 
60% aft er 10 years. In fact, we have found that endoscopica-
lly diagnosed recurrence occurs in 70% to 90% of patients 
within 1 year following surgery. Depending on the severity 
diagnosed endoscopically, these diagnoses are then correla-
ted with clinical recurrence (38).
Risk factors for surgical recurrence of Crohn’s disease 
include stricturing or penetrating patt ern, age at initial sur-
gery (younger patients have greater risks of recurrence), 
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smoking, ileocolonic locations and time elapsed between 
diagnosis and fi rst surgery. Th e rates of clinical and endos-
copic recurrence in patients with Crohn’s disease aft er fi rst 
surgery according to diff erent treatments and diff erent 
studies are as follows: placebo (25% to 77%, 53% to 79%), 
5-ASA (24% to 58%, 63% to 66%), budesonide (19% to 
32%, 52% to 57%), nitroimidazoles (7% to  8%, 52% to 
54%), thiopurines (34% to 50%, 42% to 44% ) and infl ixi-
mab (0%, 9%) which is the most eff ective. A management 
algorithm proposed by Regueiro is shown in Figure 1. Th is 
algorithm is important for determination of postsurgical 
risks facing individual Crohn’s disease patients. It indicates 
endoscopic fi ndings and risk factors to look for to provide 
the best treatment for our patients (39). 
A recent systematic review found that 67%, of patients 
with severe ulcerative colitis admitt ed to the emergency 
room responded to intravenous steroids (hydrocortisone 
and methylprednisolone). 29% of them required colecto-
mies. Th e mortality rate was 1% (40). 6% to 7.9% of them 
developed toxic megacolon with a mortality rate of around 
19%. Th e mortality rate increased to 41.5% for patients 
with perforations (41). Th ere are two major dilemmas in 
management of these individuals’ care: how to identify 
patients at high risk for complications and when to start res-
cue therapy (Infl iximab or cyclosporine) to prevent colec-
tomy. Although there are no comparative studies between 
these two drugs, infl iximab is preferable to cyclosporine for 
patients previously exposed to azathioprine. Th e long-term 
results for patients who have avoided surgery with rescue 
therapy show that 80% of patients treated with cyclosporin 
required colectomies aft er 7 years whereas with infl iximab 
50% required colectomies 3 years later. Th erefore, some 
authors suggest that these drugs diff er from surgery only in 
the percentage of cases, but this would be elective when it 
would improve a patient’s prognosis (46). 
It has been found that patients with more than 12 stools 
on the second day of treatment have a 55% risk for colec-
tomy whereas those with more than 8 stools on the third 
day have an 85% risk. One study found that when levels of 
CRP are over 45 mg/L on the third day and the number of 
stools is from 3 to 8 per day the risk of colectomy increases 
to 85%. Other risk factors include albumin <3.0 g/dl, levels 
of fecal calprotectin > 1922 mg/g, colonic dilatation> 5.5 
cm as diagnosed by abdominal x-rays (75% risk of colec-
tomy) and colonoscopic diagnosis of deep ulcers (93% risk 
of colectomy) (42). Flexible sigmoidoscopy is preferable 
to total colonoscopy for patients with severe acute ulcera-
tive colitis due to the high risk of perforation. Preferably 
this procedure should be conducted without colonic pre-
paration, with minimal infl ation, and always with biopsies 
1. 1st Occurrence of Short Stenosis > 10 years
2. Infl ammatory Crohn’s Disease, < 10 years, long stenosis
3. > 2 Penetrating Crohn’s Disease





Colonoscopy in 6 to 12 
Months
No Recurrence Recurrence
Colonoscopy in 1 to 3 
Years AZA or Anti-TNF
No Recurrence Recurrence
Colonoscopy in 1 to 3 
Years  ↑ Anti-TNF




Colonoscopy in 6 to 12 
Months
Prognosis for Post Surgery 
Recurrence
Rev Col Gastroenterol / 26 (3) 2011208 Review article
to rule out infection with cytomegalovirus (CMV). Th is 
is especially important for patients with prior exposure to 
steroids or azathioprine (6,46). 
In conclusion, we recommend starting “rescue” therapy 
in patients with severe ulcerative colitis who do not res-
pond to initial treatment with intravenous steroids aft er 
3 to 5 days of treatment. In cases of partial responses on 
the third day, one might continue steroids for up to 7 days 
before starting rescue therapy (47). Please note the risk 
factors mentioned above, and talk with patient and family 
about future management possibilities using infl iximab or 
cyclosporine. Also, talk to the gastrointestinal surgeon or 
coloproctologist about the high risk of colectomy in these 
cases. Sometimes, it is preferable to perform a colectomy in 
time and not risk the patient’s life since there are high risks 
of mortality associated with complications from severe 
acute ulcerative colitis. 
QUALITY IN THE PREVENTION OF IBD COMPLICATIONS 
Medical treatment of patients with IBD involves increased 
use of immunosuppressive drugs which increase risks of 
infections. Some of these are preventable with the use of 
vaccinations. Th erefore, it is important to check the vacci-
nation status of patients at the time of the initial consulta-
tion, ideally at the time of diagnosis. Guidelines for immu-
nization in patients with infl ammatory bowel disease (13) 
recommend annual vaccinations against infl uenza with 
inactivated trivalent vaccine, polyvalent pneumococcal vac-
cine every 5 years (Pneumovax 23), screening of patients at 
risk for hepatitis B prior to immunosuppression and vacci-
nation with three doses (0, 1 and 6 months), tetanus toxin 
vaccine every 10 years and quadrivalent human papilloma 
virus vaccination in 3 doses for women between 9 and 26 
years of age. Quadrivalent human papilloma virus vacci-
nation is also recommended for immunosuppressed men 
in the same age range who have perianal Crohn’s disease 
due to risks of HPV infection and anal cancer. Avoid 
vaccination with live and att enuated viruses for patients 
undergoing immunosuppressive therapy. Th erefore chic-
kenpox vaccinations in 2 doses are recommended prior to 
immunosuppression, as is yellow fever vaccine for travelers 
patients to endemic areas (14,43,50). 
Smoking is a risk factor for Crohn’s disease. Smokers have 
higher rates of relapse, hospitalization, and greater need for 
immunosuppressants and surgery than do nonsmokers. A 
prospective French study of 59 Crohn’s disease patients 
who stopped smoking showed that they had a 65% lower 
one year relapse rate than did Crohn’s disease patients 
who continued to smoke (15). Another study by the same 
French group found that in a follow up of 12 years, the 
proportion of years with active disease in non-smokers 
patients with Crohn’s disease was signifi cantly lower than 
that of light smokers (1 to 10 cigarett es/day) and of heavy 
smokers (more than 10 cigarett es/day) (37% vs. 46% vs. 
48%, P <0.001) (16). It appears that smoking has delete-
rious eff ect on the clinical course of patients with Crohn’s 
disease, independent of the number of cigarett es consumed 
per day by the patient, and that the prognosis for people 
who discontinue smoking is similar to that of nonsmokers.
 For screening for colon cancer in patients with IBD we 
recommend colonoscopic biopsies (2 to 4 samples every 10 
cm) for any patient with ulcerative colitis 8 to 10 years aft er 
onset of symptoms. Optimally, biopsies should be when 
the disease is in clinical remission. Th ereaft er, patients with 
extensive or left  colitis require follow-up biopsies every 1 
or 2 years, and annual colonoscopies aft er 20 years have 
passed from symptom onset. Patients with primary asso-
ciated sclerosing cholangitis and patients who have family 
histories of fi rst-degree colorectal cancer require annual 
monitoring. Individuals with proctitis or proctosigmoi-
ditis are not at increased risk of colon cancer and require 
the same assessment as the general population according 
to their ages. Crohn’s disease patients with colonic invol-
vement of at least one third of its length require screening 
colonoscopies for colorectal cancer 8 to 10 years aft er onset 
preferably when the disease is in clinical remission. If it is 
negative for cancer, it requires follow-up every 1or 2 years, 
and annual colonoscopies aft er 20 years have passed from 
symptom onset (21,22). 
One third of patients with IBD have recurrent anemia 
(hemoglobin <12 g/dl), a fi nding given litt le importance 
by  physicians, but which is responsible for many symptoms 
such as dyspnea, tachycardia, chronic fatigue, nausea, and 
cognitive impairment all of which impair patient quality of 
life. Th e most common cause of anemia is iron defi ciency 
and anemia associated with chronic disease. Other less fre-
quent causes of anemia include vitamin B 12 defi ciencies. 
Th is is especially the case for Crohn’s disease patients with 
a history of ileal resection or those with ulcerative colitis 
with ileal pouches. It can also be associated with folic acid 
defi ciency in patients with inadequate food intake. Also, 
certain medications such as 5-ASA derivatives have been 
associated with hemolysis, and the myelosuppressive eff ect 
of thiopurines such as azathioprine can cause anemia asso-
ciated with pancytopenia (23).
If possible, maintain Hb levels should be kept over 12 
g/dL for female IBD patients and over 13.5g/ dL for male 
IBD patients. Hemoglobin, hematocrit and ferritin levels of 
in patients in remission should be monitored every 6 to 12 
months. Patients with active IBD cases should be checked 
every 3 months. In case of macrocytosis or risk factors for 
vitamin B 12 or folic acid defi ciency, they should be measu-
red annually. In patients with anemia and without clinical 
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or laboratory signs of infl ammation (CRP, leukocytosis), a 
ferritin level <30 mg/L and a transferrin saturation below 
16% is indicative of iron defi ciency anemia. In case of infl a-
mmation, the lower limit of ferritin allowed is 100 mg/L. 
Th e diagnostic criteria for anemia associated with chronic 
diseases are ferritin levels > 100 mg/L and transferrin satu-
ration below 16% (24). 
In the treatment of anemia in patients with IBD the 
goal is an increase of 2 g/dL of hemoglobin in 4 weeks. 
Th e ideal is to achieve a ferritin level over 100 mg/L and 
transferrin saturation between 16% and 50%. Th e simplest 
treatment is the start of oral iron. However, this is ruled 
out for patients with Crohn’s disease with involvement of 
small intestine where local Fenton reaction producing free 
radicals that imply increased infl ammation is likely. A dose 
of 100 mg/day of elemental iron is suffi  cient, considering 
that the body can only absorb 10 mg/day. However, the 
parenteral route is preferred over oral iron for rapid and 
prolonged response, good tolerance and improvement of 
quality of life. Th e total dose of parenteral iron is 1,200 mg 
intravenously over 4 weeks, 200 mg diluted in 250 ml of 
saline solution administered twice weekly for 2 weeks. Th is 
should be followed by 200 mg weekly for another 2 weeks. 
Th is treatment is eff ective in 65% of patients. Absolute 
indications for the use of parenteral iron are the presence 
of severe anemia (Hb <10 g / dL), intolerance (21%) and 
lack of response to oral iron. Patient preference and severe 
infl ammatory involvement of small intestine must also be 
considered. Agents such as erythropoietin are indicated in 
anemia associated with chronic illnesses and when there is 
no response to parenteral iron (23,24). 
Th e overall prevalence of osteoporosis in patients with 
IBD is around 15%, but obviously varies according to 
patients’ ages. Patients with this condition have a relative 
risk of fracture of 1.3 to 1.4 times greater than the general 
population. Th is risk is slightly higher for Crohn’s disease 
patients than for those with ulcerative colitis. Aft er 6 mon-
ths of corticosteroid treatment at doses> 7.5 mg/day, there 
is a 50% risk of osteoporosis and a 50% risk of fracture. It 
is suggested bone densitometry should be performed for 
all patients with IBD with previous fractures or fi rst degree 
fractures, with previous use of steroids (prednisone> 
7.5 mg/day for more than 3 months), postmenopausal 
women, men over 50 years of age and people with lower 
than normal body mass indexes to rule out osteoporosis. 
Th is should be repeated every 2 to 3 years. General measu-
res for prevention of osteoporosis include adequate daily 
calcium (1,200 mg) and vitamin D (400-800 IU) intakes, 
exercise, avoidance of smoking and alcohol, and limitation 
of prolonged use of steroid medication savers such as aza-
thioprine and anti-TNF. On the other hand it is important 
to reduce infl ammation in patients with IBD to decrease 
osteoclast activity. When osteoporosis (T score <-2.5) is 
present bisphosphonate management should be prescri-
bed. For patients who require steroids, use of bisphospho-
nates should be initiated when their T scores fall below -1.0 
(25, 26). 
IBD patients have three times higher risk of thromboe-
mbolic events than does the general population. Among 
them there is a predominance of deep vein thrombosis 
and pulmonary embolism with an estimated incidence of 
1% to 6.7%, and these tend to occur at younger ages. Th is 
procoagulant state is due to congenital and acquired pro-
thrombotic factors, the latt er of which is more important. 
Among inherited factors, the most common are mutation 
of Leiden V factor, homozygous mutation C667T in the 
methylenetetrahydrofolate reductase gene and mutation 
20210A in the prothrombin gene. It is advisable to study 
these disorders in IBD patients with a history of thromboe-
mbolic events. Among acquired factors are infl ammation, 
prolonged immobilization, hyperhomocysteinemia (nutri-
tional defi ciencies of vitamin B12, vitamin B6 and folic 
acid), smoking, surgery, central venous catheters, steroid 
therapy and oral contraceptive use. Prophylaxis with hepa-
rin should be performed for venous thrombosis in patients 
with these risk factors (32, 33, 34).
With the advent of biological therapy, particularly anti-
TNF for patients with IBD, a concern about reactivation 
of latent tuberculosis has arisen. Th is concern is especially 
important in third world countries like ours where reac-
tivation could have serious public health repercussions. 
An FDA report 10 years ago found 70 cases of active 
tuberculosis in 147,000 patients treated with infl iximab. 
Infections were diagnosed on average 12 weeks aft er star-
ting treatment with this drug. 56% of these cases were 
extrapulmonary, while 24% had disseminated or miliary 
presentations (27). Th ese data were collected prior to the 
current recommendation of routine screening chest x-rays 
and tuberculosis testing for all patients prior to initiation of 
anti-TNF therapy. Recent data show that the incidence of 
tuberculosis in patients with IBD has declined signifi cantly 
with the implementation of screening. 
All individuals should be informed of tuberculosis risks 
prior to initiation of anti-TNF treatment, and should sign 
an informed consent form. Every patient should have 
chest x-rays. Th ey should also have an intradermal tuber-
culin test despite its low specifi city, the infl uence of BCG 
vaccination in its results (fi rst 10 years), and possible false 
negative results related to anergia associated with steroids 
and immunosuppressive therapy (up to 83%). Recently 
an alternative method of diagnosing latent tuberculosis 
has been developed. It is a QuantiFERON-TB or T-SPOT.
TB test that measures production of gamma interferon 
in T lymphocytes in response to in vitro stimulation with 
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antigens from Mycobacterium tuberculosis not present in 
the vaccine (BCG). Th is makes it more specifi c than the 
tuberculin test. Furthermore, its result are not altered even 
in the presence of immunosuppressive therapy. It has been 
found that in patients with prior application of tuberculin 
QuantiFERON results can be altered. Th is can be avoided 
by applying the latt er during the fi rst 15 days aft er applica-
tion of the fi rst. Patients with latent tuberculosis (positive 
tuberculin test with hardening > 5 mm or abnormal chest 
radiograph) should be treated with isoniazid 300 mg/day 
for 9 months ending 1 month before the start of the fi rst 
application of anti-TNF. Th is has been shown to reduce inci-
dence of tuberculosis by 70%. Anti-TNF should be imme-
diately discontinued in cases of active tuberculosis (28). 
Th e British Th oracic Society recommends that tuberculin 
test or QuantiFERON testing be repeated annually during 
maintenance of patients in anti-TNF therapy due to the risk 
of tuberculosis infection “de novo” with this treatment (50). 
In addition, there are documented cases of reactivation 
of chronic hepatitis B infection in patients with anti-TNF. 
Th erefore, application of surface antigen (HBsAg) and 
anti-core (anti-HBcore) prior to starting anti-TNF is recom-
mended. If the HBsAg is positive, viral load should be sent, 
e antigen antibody to e antigen (HBeAg and anti-HBe). If 
the viral load (DNA) is> 20,000 copies and the HBeAg is 
positive, patients are called active carriers. Anti-TNF should 
be discontinued and hepatitis B should be treated as active. 
Patients with <20,000 copies are inactive carriers. For these 
patients chemoprophylaxis should be initiated with lamivu-
dine 100 mg/day (if less than 12 months due to risk of resis-
tance), 2 weeks before the start of anti-TNF and 3-6 months 
aft er discontinuance of anti-TNF with follow-up tests for 
ALT and viral load every 1 to 3 months during treatment. 
Patients without previous vaccinations for hepatitis B or with 
low levels of antibodies against HBsAg should be vaccinated. 
Th ere is no evidence that treatment with anti-TNF exacer-
bates the course of hepatitis C infection, however we recom-
mend monitoring ALT and viral loads of these patients. It is 
also advisable to request proof of human immunodefi ciency 
virus or acquired immune defi ciency syndrome (AIDS) 
prior to initiating anti-TNF (28, 43, 44, 45). 
Increased incidence of non-melanoma type skin cancers 
have been found in patients with IBD compared to the 
general population (RR 1.64). Th e persistent use of aza-
thioprine (OR 4.27) and biological therapy (OR 2.18) are 
risk factors for cancer development. Previous studies have 
shown that azathioprine increases the photosensitivity of 
human skin, so patients are advised to avoid sun exposure 
and use sunscreen daily. Where possible, they should be 
evaluated by a dermatologist (29,30). 
Th e CESAME study group in France found an incidence of 
lymphoproliferative disease in patients receiving azathioprine 
of 0.9/1,000 patients/year. Its incidence was 0.20/1,000 
patients/year among those who stopped treatment and 
0.26/1,000 patients/year among those who never received 
azathioprine for management of IBD (p = 0.0054). Th e rela-
tive risk was 5.28 among those receiving thiopurines compa-
red to those not treated with this drug. A more interesting fi n-
ding is that patients less than 50 years of age had an incidence 
of 0.37/1,000 patients/year, between 50 and 60 years of age 
incidence was 2.58/1,000 patients/year and for patients over 
the age of 65 the incidence was 5.41/1,000 patients/year. All 
of this indicates the need for caution when considering the 
use of azathioprine for patients over 65 years old given the 
risk of lymphoproliferative disease (31). 
In recent years there has been an increase in Clostridium 
diffi  cile, anaerobic gram positive bacteria that damage the 
tissues by producing toxins A and B in patients with IBD. It 
leads to a more aggressive and severe course than among IBD 
patients than it does in people without IBD. Th e prevalence of 
this infection in IBD patients in acute crisis ranges from 5% to 
18% of cases. It can be diagnosed by ELISA for toxin A and B 
in stool. In case of a negative result in initial sampling and an 
uncertain diagnosis, repeating the test increases its sensitivity. 
Risk factors include previous exposure to antibiotics (only 
40% in IBD), the use of immunosuppressants (OR 2.58), 
previous use of proton pump inhibitors, advanced age, patient 
comorbidities and person-to-person infection. Clostridium 
diffi  cile infection increases the time of hospitalization and 
the risk of colectomy (OR: 6.6). Currently high suspicion of 
Clostridium diffi  cile infection is recommended for patients 
with severe IBD activity and presence of risk factors. An 
ELISA test for toxins A and B in the stool should be perfor-
med, and, if Clostridium diffi  cile is diagnosed, early treatment 
should be started to prevent severe complications such as 
toxic megacolon and the need for surgery. Measures to isolate 
infected patients from contact are important, and it should be 
remembered that alcohol can not destroy the spores of this 
organism. Aft er contact with the patient or patient’s environ-
ment, wash with soap and water to sweep off  spores (35).
Finally, women with IBD on immunosuppressive therapy 
and most smokers have a higher rate of abnormal cervical-
vaginal cytology (CCV) than does the general population. 
Th ese abnormalities could be related to increased rates of 
infection by human papillomavirus (HPV). A study by 
Sunanda Kane showed that 42.5% of patients with IBD had 
abnormal CCVs compared to only 7% of controls without 
IBD. In addition the study found that those undergoing 
immunosuppressive therapy for more than six months had 
50% more abnormal CCVs . All lesions showed high-risk 
HPV (+) (36). CCV is currently recommended annually for 
all women with IBD, especially those undergoing immuno-
suppressive therapy. Women patients between the ages of 9 
to 26 should be vaccinated against HPV, ideally before the 
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onset of sexual intercourse. 3 doses of vaccine, one every 2 
months should be applied. Th is protects against types 16 
and 18 (responsible for 70% of cervical cancers), and against 
HPV types 6 and 11 associated with genital warts (37,50).
Infl ammatory bowel disease is a non-curable disease, 
which requires medical management and/or surgical 
treatment to maintain disease remission and if possible 
achieve mucosal healing, improve quality of life, minimize 
complications of the disease and monitor adverse events 
associated with drugs used. Tables 1, 2 and 3 summarize 
a series of recommendations that will help us off er quality 
management for our patients.
Table 1. Summary of quality management recommendations for IBD patients. 
Quality of Treatment
• Patients with mild to moderate activity ulcerative proctitis should receive topical management with 5-ASA as fi rst line therapy.
• Mild to moderate extensive ulcerative or left colitis which does not respond to oral 5-ASA should be treated with topical 5-ASA before the use of steroids.
• Individuals with IBD who require steroid therapy should receive remission induction, not as maintenance, for a period not exceeding 12 to 16 weeks.
• Patients with IBD who require 2 or more courses of steroids per year should receive steroid saving drugs such as azathioprine or biological therapy.
• The most effective dose of azathioprine for Crohn’s disease patients is 2.5 mg/k/day.
• Before surgery, patients with IBD should stop steroid and biological therapy due to risk of postoperative complications. 
• The use of azathioprine appears to be safe.
• The minimum suspension of medication before surgery is 6 weeks for steroids and 8 to 12 weeks for infl iximab.
• Following surgical resection patients with Crohn’s disease are at high risk of recurrence of the disease and surgery. They should be 
colonoscopically evaluated and those at high risk should be aggressively managed.
• Patients with severe ulcerative colitis who do not respond to initial intravenous steroid treatment within 3 to 5 days of treatment and who have 
associated risk factors should be offered rescue therapy with infl iximab or cyclosporine.
• For cases of severe acute ulcerative colitis fl exible sigmoidoscopy with colonic biopsies and without colonic preparation is preferable to total 
colonoscopy due to high risk of perforation.
Table 2. Summary of quality management recommendations for patients with IBD
Quality in Prevention of Complications Associated with IBD
• Every Crohn’s disease patient who smokes should be advised to stop.
• All patients with ulcerative colitis and Crohn’s disease with colonic involvement require screening for colorectal cancer 8 to 10 years after diagnosis 
(preferably when in clinical remission) followed by additional screening every year or two depending on individual risk.
• Iron defi ciency anemia in patients with IBD is common and affects patients’ life quality. Ideally Hb levels should be maintained above12 g/dL for 
women and above 13.5 g/dL for men, with ferritin levels above 100 mg/L.
• In severe iron defi ciency anemia (Hb <10g/dL) substitution of oral iron is ineffective. In such cases treatment with parenteral iron is needed to 
achieve ferritin levels over 100 mg/L.
• IBD patients hospitalized with infl ammatory activity, prolonged immobilization or post-surgical procedures, should receive prophylaxis for deep vein 
thrombosis.
• Patients with IBD with disease activity and risk factors for Clostridium diffi cile infection should have ELISA tests for toxin A and B. If positive early 
treatment should begin.
Table 3. Summary of quality management recommendations for IBD patients.
Quality in Prevention of Complications Associated with Treatment
• It is important to verify vaccination status of all patients with IBD upon diagnosis.
• It is important to immunize all Hepatitis B virus negative patients with IBD at diagnosis against this virus. Serological response to the vaccine must 
be confi rmed because vaccine effi cacy is affected by the use of immunosuppressants and anti-TNF.
• We recommend annual infl uenza vaccinations, pneumococcal vaccinations every 5 years, tetanus vaccinations every 10 years, human papillomavirus 
vaccinations for females from 9-26 years of age), and measles and yellow fever vaccinations before the start of immunosuppression.
• Patients with IBD with risk factors for osteoporosis should have bone densitometry every 2-3 years.
• Prior to initiating anti-TNF therapy every patient must have chest x-rays, tuberculin skin tests (ideally prior to the use of steroids and 
immunosuppressants), and blood tests for hepatitis B and C and for AIDS.
• Patients with abnormal chest x-rays and positive tuberculin skin test should receive prophylaxis with isoniazid 300 mg/day for 9 months until 1 
month before the start of anti-TNF.
• Patients who are chronically managed with azathioprine have increased risks of non-melanoma skin cancer, so they should avoid sun exposure 
and use sunscreen.
• Use special care with the use of azathioprine in the over 65 year old population due to the risk of lymphoproliferative disease.
• Annual cervical-vaginal cytology is recommended for all patients with IBD, especially those with immunosuppressive therapy.
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